Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, ...
Ceramides-lipid molecules in cells that affect many physiological functions including cell differentiation, migration, and ...
Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...
Beyond the physical, a prostate cancer diagnosis carries significant emotional weight. Understanding this spectrum of ...
Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...
Medical Device Network on MSN
Olympus agrees $270m BioProtect buyout to expand prostate cancer offerings
BioProtect’s lead product is a spacer system designed to protect healthy tissues during radiation therapies for prostate ...
CHICAGO -- Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in ...
Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.
Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results